Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Naloxone for Opioid-Induced Constipation
NCT00020605Phase 3Unknown
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2000
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Naloxone with Placebo (2 arms). Primary endpoint: Long-term safety and efficacy of oral naloxone at 72 weeks. Status: unknown.
02
Drugs
naloxone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT00020605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020605.